鋰電池負極包覆材料行業領先企業信德新材(301349.SZ)IPO擬發行1700萬股 8月26日開啟申購
格隆匯8月17日丨鋰電池負極包覆材料行業領先企業信德新材(301349.SZ)披露招股意向書,此次發行股票數量為1700萬股,佔發行後公司總股本的25%。初步詢價日期為2022年8月22日,申購日期為2022年8月26日。
2019年度-2021年度,公司營業收入分別約為2.30億元、2.72億元及4.92億元;歸屬於母公司所有者的淨利潤分別為7262.96萬元、8611.60萬元及1.38億元。
此次募資擬投向年產 3 萬噸碳材料產業化升級項目、研發中心項目和補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.